• NuWays reiterated Buy on NanoRepro in its Nov. 3, 2026, report, maintaining a 12-month price target of EUR 4.4.
• Paedi Protect’s first-half 2026 sales reached EUR 10.9 million, exceeding NuWays’ EUR 10.6 million forecast.
• The holding company’s EBITDA loss narrowed to EUR 800,000 from EUR 1 million a year earlier as costs declined.
• Newkee secured a German drugstore online listing starting January 2027; NuWays estimates a potential permanent shelf listing could generate EUR 1–2 million annually.
• Consolidated full-year 2025 and first-half 2026 reports were delayed until year-end 2026 because of additional consolidation work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoRepro AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27286) on November 03, 2026, and is solely responsible for the information contained therein.